Back to Search Start Over

Organic-inorganic hybrid nanoparticles controlled delivery system for anticancer drugs.

Authors :
Di Martino, Antonio
Guselnikova, Olga A.
Trusova, Marina E.
Postnikov, Pavel S.
Sedlarik, Vladimir
Source :
International Journal of Pharmaceutics. Jun2017, Vol. 526 Issue 1/2, p380-390. 11p.
Publication Year :
2017

Abstract

The use of organic-inorganic hybrid nanocarriers for controlled release of anticancer drugs has been gained a great interest, in particular, to improve the selectivity and efficacy of the drugs. In this study, iron oxide nanoparticles were prepared then surface modified via diazonium chemistry and coated with chitosan, and its derivative chitosan-grafted polylactic acid. The purpose was to increase the stability of the nanoparticles in physiological solution, heighten drug-loading capacity, prolong the release, reduce the initial burst effect and improve in vitro cytotoxicity of the model drug doxorubicin. The materials were characterized by DLS, ζ-potential, SEM, TGA, magnetization curves and release kinetics studies. Results confirmed the spherical shape, the presence of the coat and the advantages of using chitosan, particularly its amphiphilic derivative, as a coating agent, thereby surpassing the qualities of simple iron oxide nanoparticles. The coated nanoparticles exhibited great stability and high encapsulation efficiency for doxorubicin, at over 500 μg per mg of carrier. Moreover, the intensity of the initial burst was clearly diminished after coating, hence represents an advantage of using the hybrid system over simple iron oxide nanoparticles. Cytotoxicity studies demonstrate the increase in cytotoxicity of doxorubicin when loaded in nanoparticles, indirectly proving the role played by the carrier and its surface properties in cell uptake. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
03785173
Volume :
526
Issue :
1/2
Database :
Academic Search Index
Journal :
International Journal of Pharmaceutics
Publication Type :
Academic Journal
Accession number :
123464524
Full Text :
https://doi.org/10.1016/j.ijpharm.2017.04.061